A carregar...
Stakeholder views on participant selection for first-in-human trials in cancer nanomedicine
BACKGROUND: Participant selection for first-in-human (fih) trials involves complex decisions. The trial design makes it unlikely that participants will receive clinically relevant therapeutic benefit, but they are likely to experience risks of various magnitudes and types. The aim of the present pap...
Na minha lista:
| Publicado no: | Curr Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5176378/ https://ncbi.nlm.nih.gov/pubmed/28050141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.23.3214 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|